Hypocholesterolemic Effect of a Phytosterol-enriched Spreadable Cream Prepared With Virgin Olive Oil

Hypocholesterolemic and Cardioprotective Clinical Evaluation of a Spreadable Cream Prepared With Virgin Olive Oil Enriched in Phytosterols and Bioactive Compounds From Olives in Children and Adolescents

This study aims to evaluate the effect of the enriched extra virgin olive oil spread in plant sterols from the olive itself and demonstrate its effect anticholesterolemic and cardioprotective in children and adolescents with hypercholesterolemia.

Study Overview

• Status: Completed
• Conditions: Hypercholesterolemia
• Intervention / Treatment: Dietary supplement: Enriched spread; Dietary supplement: Control spread

Detailed Description

A clinical study of nutritional intervention, randomized with double blind, adjusted by randomization blocks that consider age and sex, and crossover of 2 months duration each period, with 1-month washout period, in 50 subjects (25 per randomization group). The study will be carried out in the Reina Sofía Universitary Hospital of Córdoba, as well as at the Institute of Nutrition and Food Technology of the University of Granada.

The effects of the enriched spread in patients on the lipid profile will be evaluated plasma and its action on biomarkers of cardiovascular risk and on the microbiota intestinal depending on the specific genotype of each subject. In addition, the presence of minor olive oil compounds present in plasma (metabolomic analysis). In this way, at the end of the project, scientific information will be available contrasted on the enriched product and its effects on cardiovascular protection, in addition to its palatability and acceptance.

The main objective is to evaluate the effect of the enriched extra virgin olive oil spread in plant sterols from the olive itself and demonstrate its effect anticholesterolemic and cardioprotective in children and adolescents with hypercholesterolemia.

As specific objectives will be determined:

• To evaluate the effect of the enriched spread on the plasmatic concentrations of total cholesterol, LDLc and other parameters of the lipid profile
• To evaluate the effect of the enriched spread on the oxidative status of LDL plasmatic
• To evaluate the effect of the enriched spread on the antioxidant defense system
• To evaluate the effect of the enriched spread on biomarkers of cardiovascular risk, including inflammatory and endothelial damage markers
• To evaluate the effect of the enriched spread on the intestinal microbiota.
• To evaluate the effect of the enriched spread on the metabolomic changes in plasma.
• To analyze the specific genotype of each volunteer

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Spain
  • Córdoba, Spain, 14004
    • Hospital Universitario Reina Sofía de Córdoba
  • Granada, Spain, 18071
    • Universidad de Granada

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age between 6 and 18 years
• Familial hypercholesterolemia
• Acceptance to participate by signing the informed consent

Exclusion Criteria:

• Children under 6 years of age
• Absence of hypercholesterolemia
• Children who receive some type of medication to control hypercholesterolemia, blood pressure, levels of glucose or dyslipidemia or any probiotic, which have invalid data for the variables of the present study
• Not to sign the informed consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Enriched spread; Children between 20-40 kg will receive a dose of 15 g of the spread (1.2 g/d of plant sterols: 0.06-0.03 g/kg of weight/d) and those with a weight between 40-60 kg will receive two doses of 15 g of the spread (2.4 g/d of plant sterols: 0.06-0.04 g/kg of weight/d)	Dietary supplement: Enriched spread; The experimental spread is made with a base made with 90% extra virgin olive oil to which plant sterols are added.
Placebo Comparator: Control spread; Children between 20-40 kg will receive a dose of 15 g of the spread (1.2 g/d of plant sterols: 0.06-0.03 g/kg of weight/d) and those with a weight between 40-60 kg will receive two doses of 15 g of the spread (2.4 g/d of plant sterols: 0.06-0.04 g/kg of weight/d)	Dietary supplement: Control spread; The control spread will be the same base spread made with extra virgin olive oil without the added plant sterols.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hypercholesterolemia	Assessing changes of plasma lipids levels from the baseline to the end of each treatment. The serum concentrations of total cholesterol (mg/dL), triglycerides (TG, (mg/dL)), high-density lipoprotein cholesterol (HDLc, (mg/dL)), and low-density lipoprotein cholesterol (LDLc, (mg/dL)), apolipoprotein A1 (Apo-A1, (mg/dL)) and apolipoprotein B (Apo-B, (mg/dL)) will be analyzed by spectrophotometry.	Month 0; Month 2; Month 3; Month 5

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Body composition	Assessing changes of body composition from the baseline to the end of each treatment. To obtain data on body composition, fat mass (kg), lean mass (kg) and total body water (kg) will be measured via bioimpedance technology using TANITA MC-780MA (Tokyo, Japan).	Month 0; Month 2; Month 3; Month 5
Body composition percentages	Assessing changes of body composition percentages from the baseline to the end of each treatment. To obtain data on body composition, fat mass (percent), lean mass (percent) and total body water (percent) will be measured via bioimpedance technology using TANITA MC-780MA (Tokyo, Japan).	Month 0; Month 2; Month 3; Month 5
Systolic blood pressure	Assessing changes of Systolic Blood Pressure from the baseline to the end of each treatment.	Month 0; Month 2; Month 3; Month 5
Diastolic blood pressure	Assessing changes of Diastolic Blood Pressure from the baseline to the end of each treatment.	Month 0; Month 2; Month 3; Month 5
Oxidation biomarkers	Assessing changes of oxidized LDL from the baseline to the end of each treatment, by using an ELISA kit	Month 0; Month 2; Month 3; Month 5
Enzymatic antioxidant status	Assessing changes on erythrocyte antioxidant enzymes (catalase, superoxide dismutase, glutathione peroxidase and glutathione reductase) from the baseline to the end of each treatment, by using spectrophotometric kits.	Month 0; Month 2; Month 3; Month 5
Non-enzymatic antioxidant status	Assessing changes on plasma liposoluble antioxidants (retinol, beta-carotene and Q-coenzyme) from the baseline to the end of each treatment, by HPLC.	Month 0; Month 2; Month 3; Month 5
Endothelial function status	Assessing changes on plasma endothelin-1 from the baseline to the end of each treatment, by using an ELISA kit.	Month 0; Month 2; Month 3; Month 5
Endothelial damage	Assessing changes on plasma VCAM , ICAM-1, E-selectin and mielopeoxidasa from the baseline to the end of each treatment, by Luminex xMAP technology.	Month 0; Month 2; Month 3; Month 5
Fecal microbiome	Assessing changes of fecal microbiome profile from the baseline to the end of each treatment. Stool DNA will be isolated with the QIAamp DNA stool mimi kit. Amplification of variable region V3-V1 of 16S gen will be sequenced using the Illunina Next Generation Sequencing MiSeg.	Month 0; Month 2; Month 3; Month 5
Plasma metabolomic analysis	A liquid chromatography platform coupled to a spectrophotometer will be used mass (LC/MS) to determine plasma metabolic profiles by targeted analyses from the baseline to the end of each treatment.	Month 0; Month 2; Month 3; Month 5
Urine metabolomic analysis	A liquid chromatography platform coupled to a spectrophotometer will be used mass (LC/MS) to determine urine metabolic profiles by targeted analyses from the baseline to the end of each treatment.	Month 0; Month 2; Month 3; Month 5

Collaborators and Investigators

• Sponsor: Universidad de Granada
• Collaborators: Maimónides Biomedical Research Institute of Córdoba; Hospital Universitario Reina Sofia de Cordoba
• Investigators: Principal Investigator: MARIA DOLORES MESA GARCIA, Universidad de Granada

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2021
• Primary Completion (Actual): June 30, 2021
• Study Completion (Actual): December 31, 2021

Study Registration Dates

• First Submitted: March 7, 2022
• First Submitted That Met QC Criteria: July 11, 2022
• First Posted (Actual): July 15, 2022

Study Record Updates

• Last Update Posted (Actual): July 19, 2022
• Last Update Submitted That Met QC Criteria: July 14, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Virgin olive oil; Plant Sterols; Hypercholesterolemic children; Olive oil polyphenols
• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Hyperlipidemias; Dyslipidemias; Hypercholesterolemia
• Other Study ID Numbers: MEDKIDS-Chol; IDI-20190983 (Other Grant/Funding Number: Centro de Transferencia Tecnológica - UGR)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No